
Product Data Sheet

Product Name: Rupatadine (UR-12592)

Cat. No.: GC31827

Chemical Properties

Cas. No. 158876-82-5

SMILES CC1=CN=CC(CN2CC/C(CC2)=C3C4=CC=C(Cl)C=C4CCC5=CC=CN=C5\3)=C1Formula C₂₆H₂₆ClN₃ M.Wt 415.96

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure **Background**

Rupatadine (UR-12592) is a potent dual PAF/H1 antagonist with K_i of 0.55/0.1 μM (rabbit platelet membranes/guinea pig cerebellum membranes). IC_{50} value: Target: PAF/H1 antagonist in vitro: Rupatadine competitively inhibited histamine-induced guinea pig ileum contraction ($\text{pA}_2 = 9.29 \pm 0.06$) without affecting contraction induced by ACh, serotonin or leukotriene D4 (LTD4). It also competitively inhibited PAF-induced platelet aggregation in washed rabbit platelets (WRP) ($\text{pA}_2 = 6.68 \pm 0.08$) and in human platelet-rich plasma (HPRP) ($\text{IC}_{50} = 0.68 \mu\text{M}$), while not affecting ADP- or arachidonic acid-induced platelet aggregation [1]. The IC_{50} for rupatadine in A23187, concanavalin A and anti-IgE induced histamine release was $0.7 \pm 0.4 \mu\text{M}$, $3.2 \pm 0.7 \mu\text{M}$ and $1.5 \pm 0.4 \mu\text{M}$, respectively whereas for loratadine the IC_{50} was $2.1 \pm 0.9 \mu\text{M}$, $4.0 \pm 1.3 \mu\text{M}$ and $1.7 \pm 0.5 \mu\text{M}$. SR-27417A exhibited no inhibitory effect [2]. in vivo: Rupatadine blocked histamine- and PAF-induced effects in vivo, such as hypotension in rats ($\text{ID}_{50} = 1.4$ and 0.44 mg/kg i.v. , respectively) and bronchoconstriction in guinea pigs ($\text{ID}_{50} = 113$ and $9.6 \text{ micrograms/kg i.v.}$). Moreover, it potently inhibited PAF-induced mortality in mice ($\text{ID}_{50} = 0.31$ and 3.0 mg/kg i.v. and p.o. , respectively) and endotoxin-induced mortality in mice and rats ($\text{ID}_{50} = 1.6$ and

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

0.66 mg/kg i.v.) [1]. rupatadine treatment improved the declined lung function and significantly decreased animal death. Moreover, rupatadine was able not only to attenuate silica-induced silicosis but also to produce a superior therapeutic efficacy compared to pirfenidone, histamine H1 antagonist loratadine, or PAF antagonist CV-3988 [3].

[1]. Merlos M, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). *J Pharmacol Exp Ther.* 1997 Jan;280(1):114-21. [2]. Queralt M, et al. In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1. *Inflamm Res.* 2000 Jul;49(7):355-60. [3]. Lv XX, et al. Rupatadine protects against pulmonary fibrosis by attenuating PAF-mediated senescence in rodents. *PLoS One.* 2013 Jul 15;8(7):e68631.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA